M
Michel Farnier
Researcher at Regeneron
Publications - 105
Citations - 7627
Michel Farnier is an academic researcher from Regeneron. The author has contributed to research in topics: Alirocumab & PCSK9. The author has an hindex of 28, co-authored 105 publications receiving 4785 citations. Previous affiliations of Michel Farnier include Merck & Co. & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Statin combination therapy and cardiovascular risk reduction
TL;DR: An overview of various agents in combination with statin therapy on cardiovascular outcomes is provided, including ezetimibe added to simvastatin therapy and other lipid-lowering agents in development.
Journal ArticleDOI
Abstract 17070: Efficacy and Safety of Alirocumab: Pooled Analyses of 1048 Individuals With Diabetes Mellitus From Five Placebo-controlled Phase 3 Studies of at Least 52 Weeks Duration
Henry N. Ginsberg,Michel Farnier,Jennifer G. Robinson,Christopher P. Cannon,Naveed Sattar,Marie T. Baccara-Dinet,Christelle Lorenzato,Maja Bujas-Bobanovic,Michael J. Louie,Helen M. Colhoun +9 more
TL;DR: The objective is to assess alirocumab (ALI) efficiencies in patients with diabetes at high risk for CVD who may not achieve adequate control of LDL-C levels with current lipid-lowering therapies.
Journal Article
Quand proposer une association d'hypolipémiants chez un patient non à l'objectif thérapeutique sous monothérapie ?
TL;DR: L’abaissement des concentrations sériques de LDL-cholestérol (LDL-C) est considéré comme le meilleur indicateur d’efficacité de the prévention cardiovasculaire par les hypolipémiants.
Journal ArticleDOI
Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia
Jean Dallongeville,Jean-Charles Fruchart,Pascal Maigret,Stefano Bertolini,Gabriele Bittolo Bon,M. Malcom Campbell,Michel Farnier,John Langan,Gerhard Mahla,Paolo Pauciullo,Cesare Sirtori +10 more
TL;DR: Atorvastatin, an agent of the new generation, appears to efficiently reduce apoB- containing lipoprotein particles containing apoC-III in hypercholesterolemic patients.
Journal ArticleDOI
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey
Michel Krempf,Ross J. Simpson,Dena R. Ramey,Philippe Brudi,Hilde Giezek,Joanne E. Tomassini,Raymond Lee,Michel Farnier +7 more
TL;DR: Compared with actual outcomes, projected LDL-C control was better if physicians used more comprehensive strategies rather than simply doubling the statin dose, and a gap in knowledge translation from guidelines to clinical practice is highlighted.